TIMOPTIC-XE Drug Patent Profile
✉ Email this page to a colleague
When do Timoptic-xe patents expire, and what generic alternatives are available?
Timoptic-xe is a drug marketed by Bausch And Lomb Inc and is included in one NDA.
The generic ingredient in TIMOPTIC-XE is timolol maleate. There are fifteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the timolol maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Timoptic-xe
A generic version of TIMOPTIC-XE was approved as timolol maleate by MYLAN on June 8th, 1990.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TIMOPTIC-XE?
- What are the global sales for TIMOPTIC-XE?
- What is Average Wholesale Price for TIMOPTIC-XE?
Summary for TIMOPTIC-XE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 33 |
Clinical Trials: | 19 |
Patent Applications: | 7,336 |
Drug Prices: | Drug price information for TIMOPTIC-XE |
What excipients (inactive ingredients) are in TIMOPTIC-XE? | TIMOPTIC-XE excipients list |
DailyMed Link: | TIMOPTIC-XE at DailyMed |
Recent Clinical Trials for TIMOPTIC-XE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of California, San Diego | N/A |
Bausch & Lomb Incorporated | N/A |
VA Office of Research and Development | Phase 3 |
Pharmacology for TIMOPTIC-XE
Drug Class | beta-Adrenergic Blocker |
Mechanism of Action | Adrenergic beta-Antagonists |
US Patents and Regulatory Information for TIMOPTIC-XE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | TIMOPTIC-XE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020330-001 | Nov 4, 1993 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Bausch And Lomb Inc | TIMOPTIC-XE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020330-002 | Nov 4, 1993 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TIMOPTIC-XE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | TIMOPTIC-XE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020330-002 | Nov 4, 1993 | ⤷ Sign Up | ⤷ Sign Up |
Bausch And Lomb Inc | TIMOPTIC-XE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020330-001 | Nov 4, 1993 | ⤷ Sign Up | ⤷ Sign Up |
Bausch And Lomb Inc | TIMOPTIC-XE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020330-002 | Nov 4, 1993 | ⤷ Sign Up | ⤷ Sign Up |
Bausch And Lomb Inc | TIMOPTIC-XE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020330-001 | Nov 4, 1993 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TIMOPTIC-XE
See the table below for patents covering TIMOPTIC-XE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Mexico | 9202807 | CONPOSICIONES Y METODOS PARA TRATAMIENTO DE GLAUCOMA POR LA ADMINISTRACION TOPICA DE T-BUTILAMINO-3(4-MORFOLIN-1,2,5-TIADIAZOL-3-ILOXI-2-PROPANOL HIDROGENO MALEATO. | ⤷ Sign Up |
New Zealand | 182022 | ANTIGLAUCOMA COMPOSITIONS COMPRISING 1-T BUTYLAMINO-3-(4-MORPHOLINO-1,2,5-THIADIAZOL-3-YLOXY)-2-PRODANOL HYDOGEN MALEATE | ⤷ Sign Up |
Spain | 2002401 | PROCEDIMIENTO PARA PREPARAR UNA COMPOSICION FARMACEUTICA DEL TIPO DE TRANSICION DE FASE LOQUIDO-GEL POR AUMENTO DE LA FUERZA IONICA. (Pharmaceutical composition of the type which undergoes liquid-gel phase transition.) | ⤷ Sign Up |
France | 2588189 | COMPOSITION PHARMACEUTIQUE DE TYPE A TRANSITION DE PHASE LIQUIDE-GEL | ⤷ Sign Up |
China | 1046094 | ⤷ Sign Up | |
Hong Kong | 42594 | Pharmaceutical composition of the type which undergoes liquid-gel phase transition | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TIMOPTIC-XE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0509752 | C990041 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306 |
0509752 | SPC/GB99/043 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804 |
0227494 | 95C0013 | Belgium | ⤷ Sign Up | PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910 |
0509752 | 49/1999 | Austria | ⤷ Sign Up | PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306 |
0509752 | 2000C/001 | Belgium | ⤷ Sign Up | PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |